Drug
Igpro20
Igpro20: highest development phase Phase 3, developed by CSL. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| IgPro20 NCT07648264 | Phase 3 | Secondary Immune Deficiency |
| IgPro20 NCT06524739 | Phase 3 | Post-COVID Postural Orthostatic Tachycardia Syndrome |
Latest
No recent events.
Follow Igpro20 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.